P/E ratio for IQVIA (IQV)
P/E ratio as of June 2023 (TTM): 35.2
According to IQVIA's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 35.1537. At the end of 2021 the company had a P/E ratio of 55.9.
P/E ratio history for IQVIA from 2013 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 55.9 | |
| 2019 | 158 | 72.36% |
| 2018 | 91.5 | 479.29% |
| 2017 | 15.8 | -64.5% |
| 2016 | 44.5 | 104.04% |
| 2015 | 21.8 | 2.93% |
| 2014 | 21.2 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | -3.82 | -110.86% | Bahamas |
 NRC Health
NRC | 36.0 | 2.41% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.